Microorganisms influence human biology without needing to leave the intestine.
One of the principal ways they do this is through chemistry.
The intestinal microbiota transforms dietary substrates, host-derived compounds and molecules produced by other microorganisms into a vast range of metabolites. Some remain largely within the intestinal lumen. Others act at the epithelial surface, enter the circulation or are further transformed by host tissues.¹–⁴
These metabolites provide a molecular language through which microbial ecology can become host physiology.
Short-chain fatty acids, bile-acid derivatives and tryptophan metabolites are among the best studied examples, but they represent only part of a much larger chemical network.¹–⁵ Microbial metabolism also contributes to transformations involving amino acids, vitamins, polyphenols, choline, carnitine, xenobiotics and pharmaceuticals.⁶–⁸
This has changed the way the microbiome is understood.
A microorganism does not need to invade tissue to influence the host.
A change in taxonomic composition does not need to be dramatic to alter microbial chemistry.
And microbial effects cannot be understood simply by asking which organisms are present.
The more mechanistic question is:
What compounds are being produced or transformed, where are they acting, and how does the host respond?
Metabolites connect ecology with physiology
Microbial metabolism begins with ecological opportunity.
Substrates reach the intestinal microbiota from food, host secretions, mucus, shed epithelial cells and other microorganisms. The pathways available within the microbial community determine how those substrates can be transformed.¹,²,⁹
The resulting metabolites can then become substrates for other microorganisms, creating metabolic networks rather than simple one-organism–one-product relationships.
Some products are absorbed by the host.
Some are consumed by neighbouring microorganisms.
Some are transformed again.
Others are excreted.
The concentration of a metabolite detected in stool therefore represents the net result of production, utilisation, absorption, transformation and transit.¹,²
This is why microbial metabolomics requires the same interpretative discipline as microbial sequencing.
Detection is not equivalent to production.
Abundance is not equivalent to flux.
And association is not equivalent to biological effect.
Short-chain fatty acids emerge from community metabolism
Short-chain fatty acids are among the most extensively studied products of microbial fermentation.
Acetate, propionate and butyrate are generated predominantly through microbial metabolism of carbohydrates that escape digestion and absorption in the upper gastrointestinal tract.¹⁰–¹²
Their production depends on the substrates available and the metabolic capacities of the microbial community.
Different organisms contribute to different steps.
Cross-feeding is common.
One microorganism may break down a complex carbohydrate and release intermediate products that another organism uses to generate butyrate or another end product.¹¹–¹³
This means that assigning a metabolite to one bacterial taxon can be misleading.
The metabolite may emerge from a metabolic network.
The ecosystem produces the function.
Butyrate illustrates host–microbial reciprocity
Butyrate provides a particularly clear example of microbial metabolism becoming host physiology.
Colonocytes can use butyrate as an important energy substrate. Its oxidation contributes to epithelial metabolism and helps maintain the relatively hypoxic epithelial environment that supports anaerobic microbial ecology.¹⁴,¹⁵
Butyrate can also influence cellular signalling through mechanisms including G-protein-coupled receptors and inhibition of histone deacetylases.¹⁰,¹⁶
These pathways have been linked experimentally to epithelial function, immune regulation and metabolic responses.¹⁰,¹⁶,¹⁷
But the statement that “butyrate is beneficial” is still too simple.
Its effects depend on concentration, cellular context, tissue location and host physiology.
A metabolite can participate in normal homeostasis without functioning as a universal therapeutic molecule.
Mechanism must remain connected to context.
Short-chain fatty acids are signals as well as substrates
Short-chain fatty acids do more than provide energy.
They can interact with receptors expressed by epithelial, immune and other host cells and influence transcriptional and metabolic programmes.¹⁰,¹⁶–¹⁸
This provides one route through which dietary substrate availability can influence host physiology indirectly through microbial metabolism.
The sequence can be conceptualised as:
dietary substrate → microbial transformation → metabolite → host sensing → biological response
But even this apparently straightforward chain contains several conditional steps.
The substrate must reach the relevant microbial community.
The necessary organisms and pathways must be present and active.
The metabolite must be produced.
It must reach the host compartment at an effective concentration.
The relevant receptor or cellular pathway must be available.
And the downstream response must occur within the physiological context being studied.
Biological plausibility at one step does not prove the entire sequence.
Bile acids are co-produced by host and microbiota
Bile acids illustrate a different form of host–microbial metabolism.
Primary bile acids are synthesised from cholesterol in the liver, conjugated and released into the intestine. Intestinal microorganisms can then deconjugate and transform them into a diverse pool of secondary bile acids.¹⁹–²¹
These compounds are not merely detergents involved in lipid absorption.
Bile acids act as signalling molecules through receptors including FXR and TGR5, influencing metabolic, epithelial and immune processes.¹⁹–²¹
The bile-acid pool is therefore jointly shaped by host synthesis, enterohepatic circulation and microbial transformation.
The host changes the substrates available to microorganisms.
Microorganisms alter the signalling molecules returned to the host.
This reciprocal metabolism makes it difficult to classify a bile-acid signature as purely microbial or purely host-derived.
It belongs to the interaction.
Tryptophan enters several biological pathways
Tryptophan metabolism provides another example of metabolic branching.
Dietary tryptophan can enter host pathways leading to serotonin or kynurenine metabolites, while intestinal microorganisms can transform tryptophan into indole and a range of indole derivatives.²²–²⁵
Some microbial tryptophan metabolites can interact with the aryl hydrocarbon receptor and other host signalling pathways involved in epithelial and immune regulation.²²–²⁴
The biological meaning of altered tryptophan metabolism therefore depends on which pathway has changed.
A reduction in circulating tryptophan does not identify the mechanism.
An increase in one indole derivative does not describe the entire tryptophan network.
And a taxonomic signature associated with tryptophan metabolism does not demonstrate metabolite production.
Again, the metabolic pathway must be measured at the appropriate level.
Microbial metabolism can influence immune regulation
The immune system is exposed to microbial metabolites as part of normal intestinal physiology.
Short-chain fatty acids and tryptophan-derived compounds can influence differentiation and activity of immune-cell populations, while bile-acid metabolites have been linked to regulation of both innate and adaptive immune responses.¹⁶,¹⁷,²³,²⁶
These findings have helped move microbiome research beyond a model in which microorganisms influence immunity primarily through microbial structural components such as lipopolysaccharide.
Microbial metabolism creates another layer of communication.
But much of the mechanistic detail comes from experimental systems.
The existence of a pathway in mice or cultured cells does not establish the magnitude of its contribution to a human clinical phenotype.
Translation remains a separate evidential step.
Metabolites can influence epithelial-barrier biology
Microbial metabolites can act directly at the intestinal interface.
Short-chain fatty acids can influence epithelial metabolism and barrier-associated signalling. Butyrate-mediated support of colonocyte metabolism and hypoxia provides one example.¹⁴,¹⁵
Indole derivatives can influence epithelial and immune pathways through receptors including the aryl hydrocarbon receptor and pregnane X receptor.²²–²⁴,²⁷
Bile-acid signalling can alter epithelial and immune physiology.¹⁹–²¹
These mechanisms provide biologically plausible routes connecting microbial metabolism with intestinal-barrier regulation.
But they should not be collapsed into a generic claim that “microbial metabolites heal the gut”.
Different metabolites act through different pathways.
Some effects are concentration-dependent.
Some metabolites can be protective in one context and harmful in another.
And the presence of a metabolite in stool does not establish its concentration at the epithelial surface.
The interface remains spatially and physiologically specific.
Microbial metabolites can enter systemic circulation
Not all microbial metabolites remain within the intestine.
Compounds produced or modified by intestinal microorganisms can be absorbed and detected systemically.²,³,⁶
This creates potential routes through which microbial metabolism can influence distant tissues.
Trimethylamine provides a well-known example.
Certain intestinal microorganisms metabolise dietary choline and carnitine to trimethylamine, which is absorbed and converted by host hepatic enzymes into trimethylamine N-oxide. Associations between this pathway and cardiometabolic outcomes have stimulated extensive investigation.²⁸,²⁹
The pathway illustrates both the power and the complexity of host–microbial co-metabolism.
Diet supplies precursors.
Microbial enzymes generate an intermediate.
Host metabolism produces the circulating compound.
Kidney function influences its concentration.
Clinical phenotype may influence several components of the pathway.
Calling TMAO simply a “microbial metabolite” therefore compresses a multistep host–microbial process into one label.
Microbial metabolism can modify drugs
The chemical activity of the intestinal microbiota extends to pharmaceuticals.
Microorganisms can activate, inactivate or chemically modify drugs, potentially altering therapeutic efficacy or toxicity.⁷,³⁰
Large-scale experimental work has demonstrated that many commonly used drugs can be metabolised by intestinal bacteria and that specific microbial genes can contribute to these transformations.⁷
This introduces another dimension of inter-individual variation.
Two people receiving the same drug may differ not only in host genetics and physiology but also in microbial capacity to transform that compound.
The microbiome can therefore participate in pharmacology.
Yet the presence of a drug-metabolising microbial gene does not establish a clinically meaningful effect in a particular patient.
The same hierarchy applies:
capacity → activity → exposure → host consequence.
Metabolite concentrations are shaped by transit and absorption
Microbial metabolite measurements are strongly influenced by gastrointestinal physiology.
Transit time affects the duration of microbial fermentation and the time available for absorption. Water content alters faecal concentrations. Host uptake can remove metabolites from the lumen. Microorganisms themselves can consume products generated by other members of the community.³¹,³²
This makes stool metabolomics particularly important to interpret carefully.
A faecal sample measures what remains at the end of a complex process.
It does not directly measure total production.
Nor does plasma concentration provide a pure measure of microbial output, because absorption, hepatic transformation, tissue utilisation and renal clearance intervene.
The biological compartment matters.
Metabolomics expands measurement — and interpretation
Metabolomics has greatly expanded the ability to investigate microbial function.
Untargeted approaches can detect broad chemical patterns, while targeted assays can quantify defined metabolites with greater analytical specificity.³,⁴
But metabolite identification can be technically challenging, and many compounds are not uniquely microbial in origin.
Some are produced by both host and microorganisms.
Others arise from diet and are subsequently modified by either system.
The term microbiota-derived metabolite should therefore be used carefully.
Ideally, microbial origin is established through experimental evidence rather than inferred solely from association with microbiome composition.
Stable-isotope tracing, gnotobiotic models, microbial culture and mechanistic experiments can help establish source and pathway.³³,³⁴
Without such evidence, the more precise term may be microbiota-associated metabolite.
Association between metabolite and disease is not mechanism
Metabolomic studies frequently identify compounds associated with clinical phenotypes.
These findings can be valuable.
They can identify pathways worthy of mechanistic investigation and sometimes provide biomarkers of exposure or disease state.
But a metabolite associated with disease may be:
- a causal mediator;
- a compensatory response;
- a consequence of altered diet;
- a consequence of medication;
- a product of changed renal or hepatic clearance;
- a marker of altered microbial ecology;
or an unrelated correlate.
The fact that a compound can exert a biological effect experimentally does not establish that the concentration observed in humans is sufficient to drive the clinical phenotype.
Dose, tissue exposure and temporality matter.
Mechanism requires more than association.
Microbial metabolites and the gut–brain axis
Microbial metabolites are also frequently invoked as mediators of microbiota–gut–brain communication.
This is biologically plausible.
Short-chain fatty acids, tryptophan metabolites, bile acids and other microbial-associated molecules can influence immune, endocrine, metabolic and neural pathways.²⁴,³⁵–³⁷
Some may act locally within the intestine and alter signals subsequently transmitted to the nervous system.
Others may enter the circulation.
Still others may influence immune-cell activity or host metabolism without directly reaching the brain.
The phrase “microbial metabolite affects the brain” can therefore conceal several very different biological routes.
The relevant question is not simply whether a metabolite is associated with a neurological or psychiatric phenotype.
It is whether the pathway connecting microbial production to neural outcome has been demonstrated.
That distinction will become particularly important when considering microbiota–gut–brain communication in the next Research territory.
Function is not reducible to one metabolite
As microbiome science has moved towards function, there is a temptation to replace taxonomic reductionism with metabolic reductionism.
Instead of searching for one “good bacterium”, we search for one “good metabolite”.
Biology is rarely so simple.
Metabolites exist within networks.
Their concentrations depend on substrates, competing pathways, microbial community structure, host absorption and tissue metabolism.
The same microbial pathway can produce several products.
The same metabolite can arise through several pathways.
And the effect of a metabolite depends on the host system encountering it.
Microbial function therefore cannot be reduced to a list of molecules any more than the microbiome can be reduced to a list of organisms.
From microbial chemistry to host response
Microbial metabolites provide some of the strongest mechanistic bridges between the intestinal microbiota and host physiology.
They show how diet can become microbial substrate, how microbial metabolism can become chemical signalling, and how those signals can influence epithelial, immune, metabolic and potentially neural systems.
But every bridge contains several steps.
Substrate availability does not prove production.
Genetic capacity does not prove activity.
Faecal abundance does not prove epithelial exposure.
Circulating concentration does not prove microbial origin.
Experimental activity does not prove clinical causality.
The value of microbial-metabolite research lies precisely in its ability to move microbiome science towards mechanism.
Its credibility depends on preserving the distinctions required to demonstrate that mechanism.
The microbiota does not communicate with the host through one language.
It participates in a changing chemical network generated jointly by food, microorganisms and host physiology.
To understand microbial metabolites is therefore not merely to catalogue molecules, but to trace the path from ecological substrate to microbial transformation, from transformation to host exposure, and from exposure to biological response.
References
- Agus A, Clément K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut. 2021;70(6):1174–1182. doi:10.1136/gutjnl-2020-323071.
- Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012;336(6086):1262–1267. doi:10.1126/science.1223813.
- Krautkramer KA, Fan J, Bäckhed F. Gut microbial metabolites as multi-kingdom intermediates. Nature Reviews Microbiology. 2021;19(2):77–94. doi:10.1038/s41579-020-0438-4.
- Visconti A, Le Roy CI, Rosa F, et al. Interplay between the human gut microbiome and host metabolism. Nature Communications. 2019;10:4505. doi:10.1038/s41467-019-12476-z.
- Postler TS, Ghosh S. Understanding the holobiont: how microbial metabolites affect human health and shape the immune system. Cell Metabolism. 2017;26(1):110–130. doi:10.1016/j.cmet.2017.05.008.
- Wikoff WR, Anfora AT, Liu J, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(10):3698–3703. doi:10.1073/pnas.0812874106.
- Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019;570(7762):462–467. doi:10.1038/s41586-019-1291-3.
- Koppel N, Maini Rekdal V, Balskus EP. Chemical transformation of xenobiotics by the human gut microbiota. Science. 2017;356(6344):eaag2770. doi:10.1126/science.aag2770.
- Flint HJ, Scott KP, Louis P, Duncan SH. The role of the gut microbiota in nutrition and health. Nature Reviews Gastroenterology & Hepatology. 2012;9(10):577–589. doi:10.1038/nrgastro.2012.156.
- Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332–1345. doi:10.1016/j.cell.2016.05.041.
- Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environmental Microbiology. 2017;19(1):29–41. doi:10.1111/1462-2920.13589.
- den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. Journal of Lipid Research. 2013;54(9):2325–2340. doi:10.1194/jlr.R036012.
- Rivière A, Selak M, Lantin D, Leroy F, De Vuyst L. Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Frontiers in Microbiology. 2016;7:979. doi:10.3389/fmicb.2016.00979.
- Donohoe DR, Garge N, Zhang X, et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metabolism. 2011;13(5):517–526. doi:10.1016/j.cmet.2011.02.018.
- Byndloss MX, Olsan EE, Rivera-Chávez F, et al. Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion. Science. 2017;357(6351):570–575. doi:10.1126/science.aam9949.
- Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Advances in Immunology. 2014;121:91–119. doi:10.1016/B978-0-12-800100-4.00003-9.
- Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451–455. doi:10.1038/nature12726.
- Kimura I, Ichimura A, Ohue-Kitano R, Igarashi M. Free fatty acid receptors in health and disease. Physiological Reviews. 2020;100(1):171–210. doi:10.1152/physrev.00041.2018.
- Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metabolism. 2016;24(1):41–50. doi:10.1016/j.cmet.2016.05.005.
- Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Current Opinion in Gastroenterology. 2014;30(3):332–338. doi:10.1097/MOG.0000000000000057.
- Fiorucci S, Distrutti E. The pharmacology of bile acids and their receptors. Handbook of Experimental Pharmacology. 2019;256:3–18. doi:10.1007/164_2019_238.
- Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host & Microbe. 2018;23(6):716–724. doi:10.1016/j.chom.2018.05.003.
- Zelante T, Iannitti RG, Cunha C, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 2013;39(2):372–385. doi:10.1016/j.immuni.2013.08.003.
- Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. Nature Communications. 2018;9:3294. doi:10.1038/s41467-018-05470-4.
- Gao J, Xu K, Liu H, et al. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Frontiers in Cellular and Infection Microbiology. 2018;8:13. doi:10.3389/fcimb.2018.00013.
- Hang S, Paik D, Yao L, et al. Bile acid metabolites control TH17 and Treg cell differentiation. Nature. 2019;576(7785):143–148. doi:10.1038/s41586-019-1785-z.
- Venkatesh M, Mukherjee S, Wang H, et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity. 2014;41(2):296–310. doi:10.1016/j.immuni.2014.06.014.
- Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57–63. doi:10.1038/nature09922.
- Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature Medicine. 2013;19(5):576–585. doi:10.1038/nm.3145.
- Spanogiannopoulos P, Bess EN, Carmody RN, Turnbaugh PJ. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nature Reviews Microbiology. 2016;14(5):273–287. doi:10.1038/nrmicro.2016.17.
- Roager HM, Hansen LBS, Bahl MI, et al. Colonic transit time is related to bacterial metabolism and mucosal turnover in the gut. Nature Microbiology. 2016;1:16093. doi:10.1038/nmicrobiol.2016.93.
- Vandeputte D, Falony G, Vieira-Silva S, et al. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016;65(1):57–62. doi:10.1136/gutjnl-2015-309618.
- Zierer J, Jackson MA, Kastenmüller G, et al. The fecal metabolome as a functional readout of the gut microbiome. Nature Genetics. 2018;50(6):790–795. doi:10.1038/s41588-018-0135-7.
- Han S, Van Treuren W, Fischer CR, et al. A metabolomics pipeline for the mechanistic interrogation of the gut microbiome. Nature. 2021;595(7867):415–420. doi:10.1038/s41586-021-03707-9.
- Cryan JF, O’Riordan KJ, Cowan CSM, et al. The microbiota-gut-brain axis. Physiological Reviews. 2019;99(4):1877–2013. doi:10.1152/physrev.00018.2018.
- Morais LH, Schreiber HL IV, Mazmanian SK. The gut microbiota-brain axis in behaviour and brain disorders. Nature Reviews Microbiology. 2021;19(4):241–255. doi:10.1038/s41579-020-00460-0.
- Needham BD, Kaddurah-Daouk R, Mazmanian SK. Gut microbial molecules in behavioural and neurodegenerative conditions. Nature Reviews Neuroscience. 2020;21(12):717–731. doi:10.1038/s41583-020-00381-0.